<DOC>
	<DOCNO>NCT02735876</DOCNO>
	<brief_summary>This study evaluate efficacy acalabrutinib combination rituximab ( Arm 1 ) versus ibrutinib ( Arm 2 ) versus acalabrutinib ( Arm 3 ) treatment relapse refractory ( R/R ) mantle cell lymphoma ( MCL ) .</brief_summary>
	<brief_title>A Study Acalabrutinib Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib Subjects With Relapsed Refractory Mantle Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Men woman ≥ 18 year age . Pathologically confirm mantle cell lymphoma ( MCL ) . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 . Agreement use highly effective form contraception study 90 day last dose acalabrutinib ibrutinib 12 month last dose rituximab ( whichever long ) . Disease relapse , refractory , ≥ 1 prior treatment regimen mantle cell lymphoma ( MCL ) . Willing able participate require evaluation procedure study protocol include swallow capsule without difficulty . Ability understand purpose risk study provide sign date informed consent authorization use protect health information ( accordance national local patient privacy regulation ) . Any history central nervous system ( CNS ) lymphoma leptomeningeal disease . Prior exposure ibrutinib Bcell receptor ( BCR ) inhibitor . Significant cardiovascular disease . Malabsorption syndrome , disease significantly affect gastrointestinal function , resection stomach small bowel , symptomatic inflammatory bowel disease , partial complete bowel obstruction , gastric restriction bariatric surgery , gastric bypass . Uncontrolled active systemic fungal , bacterial , viral , infection . Known history infection human immunodeficiency virus ( HIV ) . History hepatitis B ( HBV ) infection active infection hepatitis C ( HCV ) . Breastfeeding pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Bruton tyrosine kinase inhibitor</keyword>
	<keyword>Btk</keyword>
	<keyword>ACP-196</keyword>
	<keyword>Mantle Cell Lymphoma</keyword>
	<keyword>MCL</keyword>
</DOC>